Literature DB >> 25264992

Combined Phacoemulsification and Ahmed Glaucoma Drainage Implant Surgery for Patients With Refractory Glaucoma and Cataract.

Felipe Valenzuela1, Andrew Browne, Miguel Srur, Carlos Nieme, Mario Zanolli, Remigio López-Solís, Leonidas Traipe.   

Abstract

PURPOSE: To examine the indications, safety, efficacy, and complications of combined phacoemulsification and Ahmed glaucoma drainage implant surgery.
METHODS: A retrospective case review of 35 eyes (31 patients) subjected to combined phacoemulsification and Ahmed glaucoma drainage implant surgery. Demographic characteristics of the study population, indications for combined surgery, and operative and postoperative complications were recorded. Visual acuity, intraocular pressure (IOP), and number of glaucoma medications were evaluated preoperatively and postoperatively. Complete success was defined as IOP ≤ 21 mm Hg without medication, qualified success if IOP ≤ 21 mm Hg with ≥ 1 medications, and failure if IOP>21 mm Hg or ≤ 5 mm Hg on ≥ 2 consecutive visits.
RESULTS: Mean follow-up was 29.5 months (range, 6 to 87 mo). The most common indication for combined surgery was a history of prior failed trabeculectomy (60%). Postoperative visual acuity improved in 30 of 35 eyes (85%) (P<0.01) regardless of the indication for combined surgery. IOP was reduced from a mean of 24.7 to 15.0 mm Hg at the last follow-up visit (P<0.01). The number of IOP-lowering medications was reduced from a median of 3.1 preoperatively to 1.7 at the last follow-up (P<0.01). Overall, there were 31 eyes (89%) classified as qualified success and 4 eyes (11%) as complete success. The most common postoperative complication was a hypertensive phase in 18 eyes (51%).
CONCLUSIONS: Combined phacoemulsification and Ahmed glaucoma drainage implant surgery seems to be a safe and effective surgical option, providing good visual rehabilitation and control of IOP for patients with refractory glaucoma and cataract.

Entities:  

Mesh:

Year:  2016        PMID: 25264992     DOI: 10.1097/IJG.0000000000000141

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  7 in total

1.  Longer-term Baerveldt to Trabectome glaucoma surgery comparison using propensity score matching.

Authors:  Tigran Kostanyan; Tarek Shazly; Kevin B Kaplowitz; Steven Z Wang; Sushma Kola; Eric N Brown; Nils A Loewen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-09-25       Impact factor: 3.117

Review 2.  Role of Cataract Surgery in the Management of Glaucoma.

Authors:  Jeanie D Ling; Nicholas P Bell
Journal:  Int Ophthalmol Clin       Date:  2018

3.  Intermediate-term outcomes of combined phacoemulsification and Aurolab aqueous drainage implant in eyes with refractory glaucoma and coexistent cataract.

Authors:  Sharmila Rajendrababu; George Varghese Puthuran; Laxmi Ananya Alia; Mohammed Sithiq Uduman; Hiruni Kaushalya Wijesinghe
Journal:  Int Ophthalmol       Date:  2022-04-20       Impact factor: 2.029

4.  Biometric Predictability in Combined Cataract Surgery and Ahmed Glaucoma Valve Implantation Depending on Tube Position.

Authors:  Ana Marta; João Coelho; Rita Vieira; Ana Figueiredo; Rita Reis; Isabel Sampaio; Maria João Menéres; Pedro Menéres
Journal:  Clin Ophthalmol       Date:  2021-05-14

5.  Combined cataract extraction with a new nonvalved glaucoma drainage device in adult eyes with cataract and refractory glaucoma.

Authors:  Divya P Rao; Vanita Pathak-Ray
Journal:  Indian J Ophthalmol       Date:  2018-09       Impact factor: 1.848

6.  Ciliochoroidal detachment after Ahmed glaucoma valve implantation: a retrospective study.

Authors:  Lin Fu; Yau Kei Chan; Li Nie; Qi Dai; Zhenbin Qian; Kendrick Co Shih; Jimmy Shiu Ming Lai; Rong Huang; Weihua Pan
Journal:  BMC Ophthalmol       Date:  2019-02-06       Impact factor: 2.209

7.  Factors Associated with Outcomes of Combined Phacoemulsification and Ahmed Glaucoma Valve Implantation.

Authors:  Junki Kwon; Kyung Rim Sung
Journal:  Korean J Ophthalmol       Date:  2018-05-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.